TYMS, thymidylate synthetase, 7298

N. diseases: 406; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease BEFREE The AUC of TYMS for predicting the efficacy of chemotherapy on colon cancer was 0.831 (95% CI, 0.735-0.926), and both had higher predictive values. 31423175 2019
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE Tumor TS levels were prospectively evaluated in two adjuvant therapy trials for patients with resected stage II or III colon cancer. 27821793 2017
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression. 29088787 2017
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease BEFREE In this study, we demonstrated for the first time, that human TS and DHFR form a strong complex in vitro and co-localize in human normal and colon cancer cell cytoplasm and nucleus. 27187663 2017
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 GeneticVariation disease BEFREE Thymidylate synthase polymorphism in Mexican patients with colon cancer treated with 5-fluorouracil. 27685916 2017
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE EMAST was more frequent in colon cancer than rectal cancer (p=0.033), and associated with MSI-H phenotype (p<0.001), low expression of hMSH3 (p=0.004), and overexpression of thymidylate synthase (p=0.006). 27889996 2016
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE Here, we demonstrate that the enhanced HSP90 function and subsequent activation of Src induce expression of TYMS and acquired resistance to 5-FU in colon cancer. 26416450 2015
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease BEFREE Regulation of TS by irinotecan was evaluated by western blotting and quantitative real-time PCR assay. dMMR accounted for 18.5 % and was related with proximal colon cancer (p = 0.005), poorly differentiated tumors (p = 0.018) and favorable efficacy with a higher disease control rate (DCR), a longer progression-free survival (PFS) and a trend of longer overall survival (OS). dMMR colon cancer cells were more sensitive to irinotecan. 26142736 2015
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease BEFREE In the present study, AQP5 and P-glycoprotein (P-gp), glutathione S-transferase-π (GST-π), topoisomerase II (TOPO II), and thymidylate synthase (TS) were checked in CC and adjacent cancer tissues; AQP5-siRNA was applied to silencing AQP5 in CC cell line HT-29, 5-fluorouracil (5-FU), and cisplatin (DDP) added on cells, and sulforhodamine B (SRB) was used; fluorescence real-time quantitative RT-PCR and Western blot were employed to detect changes in multidrug resistance factor and expression mitogen-activated protein kinase (MAPK) signaling pathway in HT-29. 24752576 2014
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease BEFREE Arsenic trioxide (ATO) has been shown to suppress TYMS in a colonic cancer model. 24691991 2014
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE These features include cellular morphology, expression of colon cancer stem cell markers, expression of survivin and thymidylate synthase and sensitivity to fluorouracil. 23674327 2013
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease BEFREE High TS was only found in 9.3% of rectal tumors, but in 29.7% of colon cancers (p=0.0042). 23968134 2013
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE This study evaluates if a combined analysis of MMR status and TS expression in colon cancer can add prognostic value and better predict response to adjuvant 5-FU-based chemotherapy. 23276521 2013
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease BEFREE We have previously shown that miR-215 suppressed the expression of key targets such as thymidylate synthase (TS), dihydrofolate reductase, and denticleless protein homolog (DTL) in colon cancer. miR-215 is a tumor suppressor candidate due to the upregulation of p53 and p21 by targeting DTL. 21752725 2011
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 GeneticVariation disease BEFREE Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. 21630057 2011
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 GeneticVariation disease BEFREE Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. 20966539 2010
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE In this study, we demonstrate that the histone deacetylase inhibitors (HDACi) vorinostat and LBH589 significantly downregulate TS gene expression in a panel of colon cancer cell lines. 19384949 2009
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 PosttranslationalModification disease BEFREE Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer. 18203297 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease CTD_human Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. 19105824 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease CTD_human In both gastric and colon cancers, thymidylate synthase and orotate phosphoribosyltransferase mRNA expressions were higher (p < 0.0001, p <0.0001 respectively in gastric cancer and P = 0.0002, p < 0.0001 respectively in colon cancer) and dihydropyrimidine dehydrogenase mRNA expressions were lower in cancer cells than in cancerous stroma (P = 0.0136 in gastric cancer and p < 0.0001 in colon cancer). 18652704 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease CTD_human 'High-expression' variants of TS 2R/3R repeat, TS enhancer region 3R G/C, TS 1494del6 bp, and TS haplotype analysis might help to identify stage II and stage III colon cancer patients who are at great risk of developing tumor recurrence, and also those who are more likely to benefit from 5-fluorouracil-based adjuvant chemotherapy. 18192902 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE Furthermore, the reduction of TS expression resulted in enhancement of the sensitivity to 5-FU in human colon cancer DLD-1 cells. 18425338 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 AlteredExpression disease BEFREE This study investigated the predictive role of TS at the DNA and protein levels in patients with N(+) colon cancer (n = 38). 18661526 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 GeneticVariation disease BEFREE Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival. 17290389 2007
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.400 Biomarker disease BEFREE In this study, a comprehensive gene expression analysis at the levels of both transcriptional and post-transcriptional regulation was conducted to identify response markers using human genome array with TS-depleted human colon cancer HCT-C18 (TS-) cells and HCT-C18 (TS+) cells stably transfected with the human TS cDNA expression plasmid. 16584549 2006